Evidence map›Paper›PMID 38902566›Full record

ArticleHuman cell2024

IL-32/NFκB/miR-205 loop sustains the high expression of IL-32 and enhances the motility of cervical cancer cells.

Jianbing Liu, Kai Yang, Xiaoyu Lin, Jing Xu, Xiaohua Cui, Jianqing Hao, Wei Wang, Wenhao Wang, Li Li, Min Hao

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Organoid technology in cervical cancer research.American journal of cancer research · 2025
    Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Jianbing Liu *Departments of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, 036000, Shanxi, China.ORCID http://orcid.org/0000-0002-8962-4324
Kai Yang *School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Xiaoyu LinSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Jing XuSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Xiaohua CuiSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Jianqing HaoSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Wei WangDepartments of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, 036000, Shanxi, China.
Wenhao WangDepartments of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, 036000, Shanxi, China.
Li LiSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, Shanxi, China. lili_5076@sxmu.edu.cn.
Min HaoDepartments of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, 036000, Shanxi, China. 2yuanhaomin@163.com.

Funding

National Natural Science Foundation of China 81972452National Natural Science Foundation of China 82272622Postdoctoral Research Foundation of China 2021M702052Shanxi Fundamental Research Program 202103021224237Shanxi Fundamental Research Program 20210302123277Shanxi Fundamental Research Program 20210302123320Shanxi Fundamental Research Program 20210302124577
6 · The paper itself

Abstract

Human papillomavirus (HPV) infection is a major contributor to cervical cancer. Persistent HPV infection can trigger the expression of IL-32, yet the precise role of IL-32 in the occurrence and development of cervical cancer remains elusive. To investigate this, qRT‒PCR and western blotting were utilized to measure the mRNA and protein expression levels; bioinformatics analysis was used to screen differentially expressed miRNAs; wound healing and transwell assays were conducted to evaluate cell migration and invasion capabilities. Comparative analysis revealed significantly elevated IL-32 expression in cervical cancer tissues and cell lines compared to control groups. In SiHa and/or HeLa, overexpression of IL-32 and IL-32 exposure markedly upregulated miR-205, whereas its knockdown resulted in a substantial downregulation of miR-205. Furthermore, miR-205 also could significantly regulate the expression of IL-32 in HeLa and SiHa cells. Upregulation and downregulation of IL-32 led to a significant increase or decrease in NFκB expression, respectively. Treatment with BAY11-7082 (an NFκB inhibitor) notably decreased miR-205 expression but had no effect on IL-32 levels. qRT‒PCR and western blotting analyses demonstrated that both overexpression and underexpression of IL-32 and miR-205 significantly enhanced or reduced MMP2 and MMP9 expression in cervical cancer cells, respectively. Knockdown of IL-32 significantly inhibited the migration and invasion of HeLa and SiHa; conversely, treatment with rIL-32α and rIL-32γ notably promoted their migration and invasion. In brief, IL-32 is highly expressed via the formation of a positive regulatory loop with NFκB/miR-205, contributing to the persistence of inflammation and promoting the progression of cervical cancer.

Indexed as

Cell MovementInterleukinsMicroRNAsNF-kappa BUterine Cervical NeoplasmsCell Line, TumorFemaleGene ExpressionGene Expression Regulation, NeoplasticHeLa CellsHumansNeoplasm InvasivenessUp-RegulationIL32 protein, humanInterleukinsMicroRNAsMIR205, humanNF-kappa BCervical cancerIL-32InvasionMigrationmiR-205

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.